EA201401200A1 - Новая композиция альфентанила для лечения острой боли - Google Patents

Новая композиция альфентанила для лечения острой боли

Info

Publication number
EA201401200A1
EA201401200A1 EA201401200A EA201401200A EA201401200A1 EA 201401200 A1 EA201401200 A1 EA 201401200A1 EA 201401200 A EA201401200 A EA 201401200A EA 201401200 A EA201401200 A EA 201401200A EA 201401200 A1 EA201401200 A1 EA 201401200A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alfentanil
treatment
acid
microparticles
acute pain
Prior art date
Application number
EA201401200A
Other languages
English (en)
Other versions
EA028110B1 (ru
Inventor
Андерс Петтерссон
Эмиль Шван
Барбро Йоханссон
Original Assignee
Орексо Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201401200(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Орексо Аб filed Critical Орексо Аб
Publication of EA201401200A1 publication Critical patent/EA201401200A1/ru
Publication of EA028110B1 publication Critical patent/EA028110B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Обеспечиваются фармацевтические композиции для лечения боли, например кратковременной боли, где композиции включают смесь, содержащую (a) микрочастицы альфентанила или его фармацевтически пригодной соли, где микрочастицы присутствуют на поверхностях частиц носителя большего размера; (b) водорастворимое слабое основание и (c) соединение, являющееся слабой кислотой, где кислота присутствует в однородной смеси с микрочастицами альфентанила или его соли. Композиция может дополнительно содержать дезинтегрант. Кислота предпочтительно является лимонной кислотой.
EA201401200A 2012-05-02 2013-05-01 Новая композиция альфентанила для лечения острой боли EA028110B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1207701.2 2012-05-02
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition
GB1221130.6 2012-11-23
PCT/GB2013/051131 WO2013164620A1 (en) 2012-05-02 2013-05-01 New alfentanil composition for the treatment of acute pain

Publications (2)

Publication Number Publication Date
EA201401200A1 true EA201401200A1 (ru) 2015-02-27
EA028110B1 EA028110B1 (ru) 2017-10-31

Family

ID=48577134

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401200A EA028110B1 (ru) 2012-05-02 2013-05-01 Новая композиция альфентанила для лечения острой боли

Country Status (33)

Country Link
US (4) US8815911B2 (ru)
EP (2) EP2849730B1 (ru)
JP (1) JP6275696B2 (ru)
KR (1) KR20150005695A (ru)
CN (1) CN104427978B (ru)
AU (1) AU2013255640B2 (ru)
BR (1) BR112014027213A8 (ru)
CA (1) CA2871805A1 (ru)
CL (1) CL2014002979A1 (ru)
CO (1) CO7170181A2 (ru)
CY (2) CY1118570T1 (ru)
DK (2) DK2849730T3 (ru)
EA (1) EA028110B1 (ru)
ES (2) ES2614757T3 (ru)
HR (2) HRP20161634T1 (ru)
HU (1) HUE031792T2 (ru)
IL (1) IL235272B (ru)
IN (1) IN2014MN02156A (ru)
LT (2) LT2849730T (ru)
ME (1) ME02644B (ru)
MX (1) MX360665B (ru)
NZ (1) NZ701428A (ru)
PE (1) PE20142444A1 (ru)
PH (1) PH12014502407A1 (ru)
PL (2) PL3150199T3 (ru)
PT (2) PT3150199T (ru)
RS (2) RS55489B1 (ru)
SG (1) SG11201407081PA (ru)
SI (2) SI3150199T1 (ru)
SM (3) SMT201800585T1 (ru)
TR (1) TR201815935T4 (ru)
WO (1) WO2013164620A1 (ru)
ZA (1) ZA201407559B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500316B1 (en) 2011-09-19 2018-10-03 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
TR201815935T4 (tr) * 2012-05-02 2018-11-21 Orexo Ab Akut ağrının tedavisi için yeni alfentanil bileşimi.
WO2017180659A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN115047109B (zh) * 2022-06-17 2024-05-31 三明海关综合技术服务中心 一种检测食品中芬太尼类新精神活性物质的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
CA2512559A1 (en) 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
KR101170844B1 (ko) 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US7858121B2 (en) * 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
EP1708686B1 (en) 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
DE602004031771D1 (de) 2003-12-31 2011-04-21 Cima Labs Inc Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1863456A1 (en) 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
AU2007275581B2 (en) * 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8470361B2 (en) * 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
CA2704929C (en) 2007-08-07 2018-05-15 Pamela Palmer Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
US20100056574A1 (en) 2008-09-04 2010-03-04 Mallinckrodt Inc. Crystalline Forms of Sufentanil
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
WO2010132605A1 (en) 2009-05-13 2010-11-18 Protein Delivery Solutions, Llc Pharmaceutical system for trans-membrane delivery
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
TR201815935T4 (tr) * 2012-05-02 2018-11-21 Orexo Ab Akut ağrının tedavisi için yeni alfentanil bileşimi.

Also Published As

Publication number Publication date
MX2014013176A (es) 2015-01-19
SI3150199T1 (sl) 2018-12-31
US20140005223A1 (en) 2014-01-02
BR112014027213A8 (pt) 2018-01-16
KR20150005695A (ko) 2015-01-14
SG11201407081PA (en) 2014-11-27
CN104427978A (zh) 2015-03-18
US20180214437A1 (en) 2018-08-02
JP2015515974A (ja) 2015-06-04
CL2014002979A1 (es) 2014-12-05
HRP20181761T1 (hr) 2018-12-28
US9782396B2 (en) 2017-10-10
AU2013255640A1 (en) 2014-11-20
SMT201700086T1 (it) 2017-03-08
US9345698B2 (en) 2016-05-24
JP6275696B2 (ja) 2018-02-14
EP3150199A1 (en) 2017-04-05
SMT201800585T1 (it) 2019-01-11
ZA201407559B (en) 2016-05-25
CY1120820T1 (el) 2019-12-11
HK1203399A1 (en) 2015-10-30
US20170071927A1 (en) 2017-03-16
DK3150199T3 (en) 2018-11-12
IL235272B (en) 2018-10-31
EP3150199B1 (en) 2018-08-08
RS57951B1 (sr) 2019-01-31
ME02644B (me) 2017-06-20
PH12014502407B1 (en) 2015-01-12
NZ701428A (en) 2016-10-28
PT2849730T (pt) 2017-02-15
SI2849730T1 (sl) 2017-02-28
HUE031792T2 (en) 2017-07-28
US8815911B2 (en) 2014-08-26
PE20142444A1 (es) 2015-01-09
CY1118570T1 (el) 2017-07-12
ES2614757T3 (es) 2017-06-01
ES2694644T3 (es) 2018-12-26
EP2849730A1 (en) 2015-03-25
CN104427978B (zh) 2017-03-01
US20150133501A1 (en) 2015-05-14
HRP20161634T1 (hr) 2017-01-13
DK2849730T3 (en) 2017-02-13
PL3150199T3 (pl) 2019-03-29
MX360665B (es) 2018-11-13
PT3150199T (pt) 2018-11-21
CA2871805A1 (en) 2013-11-07
CO7170181A2 (es) 2015-01-28
PH12014502407A1 (en) 2015-01-12
PL2849730T3 (pl) 2017-05-31
AU2013255640B2 (en) 2017-06-15
TR201815935T4 (tr) 2018-11-21
EA028110B1 (ru) 2017-10-31
WO2013164620A1 (en) 2013-11-07
EP2849730B1 (en) 2016-11-09
LT2849730T (lt) 2016-12-27
SMT201700086B (it) 2017-03-08
LT3150199T (lt) 2018-11-12
BR112014027213A2 (pt) 2017-06-27
RS55489B1 (sr) 2017-04-28
IN2014MN02156A (ru) 2015-08-28

Similar Documents

Publication Publication Date Title
UA110612C2 (ru) Производные 1-амино-2-циклопропилетилбороновои кислоты
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12015502792A1 (en) Crystalline bromodomain inhibitors
EA033374B1 (ru) Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
MY162146A (en) Pharmaceutical composition
WO2015056094A3 (en) Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent
EA201490760A1 (ru) R(+)-n-метилпропаргиламиноиндан
EA201490688A1 (ru) 2-тиопиримидиноны
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
CY1120820T1 (el) Νεα συνθεση αλβαιντανυλης για την αγωγη του οξεος πονου
EA201401309A1 (ru) Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU